Other links:

Other links:

Basudeb Maji

Assistant Professor of Biology and Chemistry, Ashoka University

Ph.D. Indian Institute of Science, Bangalore

Basudeb is an Assistant Professor of Biology in the Trivedi School of Biosciences. He is also affiliated as an Assistant Professor of Chemistry at Ashoka University. He did his Ph.D. at the Indian Institute of Science, Bangalore and he was a Postdoctoral Fellow at Harvard Medical School and MIT. His research group works on Synthetic Biology and Chemogentics to address various genetic and infectious diseases. He primarily uses CRISPR-based genome engineering, protein engineering, and chemical biology methods to understand the biology underlying various diseases and their chemopreventive development.

For an updated list, please follow the Google Scholar link

  1. M Lee#,¬†B Maji#, D Manna#, J Small, B Wagner, A Choudhary.¬†Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in ő≤-Cells. Journal of the American Chemical Society, 2020,142, 6477-6482. # Equal contribution. (IF 14.6)

  2. B Maji, SA Gangopadhyay, M Lee, M Shi, P Wu, R Heler, B Mok,¬†D Lee, B Paul, V Danńć√≠k, MF Mesleh, A Vetere, LA Marraffini, DR Liu, PA Clemons, BK Wagner and A Choudhary.¬†A high- throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell, 2019, 167, 1067- 1079. Highlighted in more than 12 science media reports.¬†(IF 38.6)

  3. B Maji,a CL Moore,a B Zetsche, SE Volz, F Zhang, MD Shoulders and A Choudhary.   Multi-Dimensional Chemogenic Control of CRISPR-Cas9. Nature Chemical Biology, 2017, 13, 9-11. aEqual contribution. (Highlighted by Nat. Chem. Biol. News & Views. doi: 10.1038/nchembio.2243.) (IF 12.6)

  4. D Manna, B Maji, S. Gangopadhyay, and A Choudhary. A singular system with precise dosing and spatiotemporal control of CRISPR-Cas9. Angew. Chem. Int., 2019, 58, 6285-6289. (IF 13.0)

  5. SA Gangopadhyay, K Cox, D Manna, D Lim,¬†B Maji, Q Zhou and A Choudhary.¬†Precision control of CRISPR-Cas9 using small molecules and light. Biochemistry, 2019, 58, 234‚Äď244.¬†(IF 3.0)

  6. MH Kaulage,a B Maji,a S Pasadi, A Ali, S Bhattacharya and K Muniyappa. Targeting G-quadruplex  DNA structures in the telomere and oncogene promoter  regions  by  benzimidazole‒carbazole ligands. European Journal of Medicinal Chemistry, 2018, 148, 178-194. aEqual contribution. (IF 5.6)

  7. N Dey,¬†B Maji¬†and S Bhattacharya.¬†Motion Induced Change in Emission as an Effective Strategy for Ratiometric Probing of Human Serum Albumin and Trypsin in a Wide Range of Biological Fluids. Chemistry ‚Äď An Asian Journal, 2018, 13, 664-671.¬†(IF 3.8)

  8. N Dey,¬†B Maji¬†and S Bhattacharya.¬†A Unique Example of Excitation Triggered Alteration in Sensing Behavior of Fluorescent Organic Nanoaggregates: A Multifaceted Detection Probe for Caffeine in Real- Life Samples. Analytical Chemistry, 2018, 90, 821‚Äď829.¬†(IF 6.8)

  9. MH Kaulage, B Maji, S Pasadi, S Bhattacharya and K Muniyappa. Novel ruthenium azo-quinoline complexes with enhanced photonuclease activity in human cancer cells. European Journal of Medicinal Chemistry, 2017, 139, 1016-1029. (IF 5.6)

  10. T Hussain, D Saha, G Purohit, A Kar, A Mukherjee, S Sharma, S Sengupta, P Dhapola, B Maji et al. Transcriptional control of CDKN1A (p21/CIP1/WAF1) by TRF2 through the REST repressor complex. Scientific Reports, 2017, 7, 11541. (IF 4.0)

  11. M Kaulage, B Maji, J Bhat, Y Iwasaki, S Chatterjee, S Bhattacharya, K Muniyappa. Discovery and Structural Characterization of G-quadruplex DNA in Human Acetyl-CoA Carboxylase Gene Promoters: Its Role in Transcriptional Regulation and as a Therapeutic Target for Human Disease. Journal of Medicinal Chemistry, 2016, 59, 5035-5050. (IF 6.2)

  12. B Maji, K Kumar, K Muniyappa, and S. Bhattacharya, New dimeric carbazole‚Äďbenzimidazole mixed ligands for the stabilization of human telomeric G-quadruplex DNA and as telomerase inhibitors. A remarkable influence of the spacer. Organic & Biomolecular Chemistry, 2015,13, 8335-8348.¬†(IF 3.6)

  13. B Maji, K Kumar, M Kaulage, K Muniyappa and S Bhattacharya,¬†Design and Synthesis of New Benzimidazole‚ÄďCarbazole Conjugates for the Stabilization of Human Telomeric DNA, Telomerase Inhibition, and Their Selective Action on Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6973-6988.¬†(IF 6.2)

  14. B Maji and S Bhattacharya, Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA. Chemical Communications. 2014, 50, 6422-6438. (IF 6.0)

  15. B Maji, SK Samanta and S Bhattacharya, Role of DNA Secondary Structures in the Reversible Dispersion/Precipitation and Separation of Metallic and Semiconducting Single-walled Carbon Nanotubes. Nanoscale, 2014, 6, 3721-3730. (IF 6.9)

  16. B Maji and S Bhattacharya, Molecular design of synthetic benzimidazoles for the switchover of the duplex to G-quadruplex DNA recognition. Chimia 2013, 67, 39-43. (IF 1.2)

  17. A Paul,¬†B Maji, SK Misra, AK Jain, K Muniyappa and S Bhattacharya,¬†Stabilization and structural alteration of the G-quadruplex DNA made from the human telomeric repeat mediated by Tr√∂ger’s base based novel benzimidazole derivatives. Journal of Medicinal Chemistry, 2012, 55, 7460-7471.¬†(IF 6.2)

  18. A Paul, AK Jain, SK Misra, B Maji, K Muniyappa and S Bhattacharya, Binding of gemini bisbenzimidazole drugs with human telomeric G-quadruplex dimers: Effect of the spacer in the design of potent telomerase inhibitors. PLoS ONE, 2012, 7, e39467. (IF 2.7)

  19. AK Jain, A Paul, B Maji, SK Misra, K Muniyappa and S Bhattacharya, Dimeric 1,3-Phenylene- bis(piperazinyl benzimidazole)s: Synthesis and structure-activity investigations on their binding with human telomeric G-quadruplex DNA and telomerase inhibition properties. Journal of Medicinal Chemistry, 2012, 55, 2981-2993. (IF 6.2)

  20. AD Tiwari, AK Mishra, SB Mishra, BB Mamba, B Maji and S Bhattacharya, Synthesis and DNA binding studies of Ni(II), Co(II), Cu(II) and Zn(II) metal complexes of N 1,N 5-bis[pyridine-2-methylene]- thiocarbohydrazone Schiff-base ligand. Spectrochimica Acta РPart A: Molecular and Biomolecular Spectroscopy, 2011, 79, 1050-1056. (IF 2.9)

  1. CRISPR-CAS systems having destabilization domains, US Patent WO/2018/005,873, 2018.

  2. Inhibitors of RNA guided nucleases and uses thereof. Pub. No.: WO/2018/085288. Publication Date:11.05.2018.

  3. Inhibitors of RNA-guided nuclease target binding and uses thereof. WO/2020/068304.

  4. Targeted delivery to beta cells. US patent WO2018195486A1 WIPO (PCT), 2018.

  5. Methods and compositions for optochemical control of crispr-cas9. WO / 2020/041380, 2018.

  6. Crispr protein inhibitors, U.S. Provisional Patent Application No. 62/579,727.

Study at Ashoka

Study at Ashoka